Epigenetics and microRNAs combine to modulate the MDM2/p53 axis in myeloma.
Avoiding the inhibitory effects of p53 on cell growth is important for tumor progression. In this issue of Cancer Cell, Picchiorri et al. describe epigenetic silencing of MDM2-targeting microRNAs in multiple myeloma (MM), which generally appears to have intact p53 function. This provides the rationale for microRNA-targeted therapy for MM.
Mayo Clinic in Arizona, Scottsdale, 85259, USA.
Marta
M
Chesi
P Leif
PL
Bergsagel